Skip to content

Development and validation of a context-specific Indian Cancer Stigma Scale (ICSS) for breast, cervical, and oral cancers.

Development of a context-specific cancer stigma scale for India. - ICSS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107319
Enrollment
200
Registered
2026-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast Health Condition 2: C069- Malignant neoplasm of mouth, unspecified Health Condition 3: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

National Cancer Grid
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) For patients participating in focus group discussions, workshops, cognitive interview and pilot testing 1)Tumor type - breast, cervical, oral 2)Diagnosed within 6 months (Patients who have been diagnosed and/or actively receiving treatment within the health system for up to six month) and their caregivers 3)Representation across centres in India covering five regions (west, east, south, central, north) 4)Representation from urban,rural and hard to reach tribal populations 5)Literate and able to give written informed consent b) For patient caregivers, Policymakers/Doctors/Nurses/Asha workers participating in focus group discussion and indepth interviews 1)Literate 2)Willing to give informed consent

Exclusion criteria

Exclusion criteria: Those experiencing significant side effects from ongoing treatment

Design outcomes

Primary

MeasureTime frame
Validity and reliability of the Indian Cancer Stigma Scale- content validity, criterion validity, internal consistency, test retest reliability, inter-rater reliabilityTimepoint: At end of phase 4, 36 months

Secondary

MeasureTime frame
a. Assessment of domains of cancer stigma (perceived, enacted, internalized, structural stigma, stigma by association)Timepoint: During pilot testing and validation phase (up to 36 months);b. Identification of key dimensions of cancer stigma in the Indian contextTimepoint: During qualitative phases (Phase 1 3 with literature review, IDIs, FGDs, cognitive interviews);c. Assessment of variation in stigma across geographic regions, gender, and socio-cultural factorsTimepoint: During pilot testing and validation phase (up to 36 months)

Countries

India

Contacts

Public ContactDr C S Pramesh

Tata Memorial Hospital, Mumbai

prameshcs@tmc.gov.in02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026